Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...
After hours: March 21 at 5:14:06 PM EDT Loading Chart for RIGL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback